Skip to main content
Erschienen in: Pituitary 4/2018

19.02.2018

Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas

verfasst von: Sema Ciftci Dogansen, Gulsah Yenidunya Yalin, Seher Tanrikulu, Sakin Tekin, Nihan Nizam, Bilge Bilgic, Serra Sencer, Sema Yarman

Erschienen in: Pituitary | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess baseline T2-weighted signal intensity (T2-WSI) of functional pituitary adenomas (FPA), and to investigate the relationship of baseline T2-WSI with clinical features, histopathological granulation patterns, and response to treatment in patients with acromegaly, prolactinoma and Cushing’s disease (CD).

Methods

Somatotroph adenomas (n = 87), prolactinomas (n = 78) and corticotroph adenomas (n = 29) were included in the study. Baseline T2-WSI findings (grouped as hypo-, iso- and hyperintense) were compared with hormone levels, tumor diameter, granulation patterns and response to treatment.

Results

Somatotroph adenomas were mostly hypointense (53%), prolactinomas were dominantly hyperintense (55%), and corticotroph adenomas were generally hyperintense (45%). Hyperintense somatotroph adenomas were larger in size with sparsely granulated pattern and tumor shrinkage rate was lower after somatostatin analogues (SSA) (p = 0.007, p = 0.035, p = 0.029, respectively). T2 hypointensity was related with higher baseline IGF-1% ULN (upper limit of normal) levels and a better response to SSA treatment (p = 0.02, p = 0.045, respectively). In female prolactinomas, hyperintensity was correlated with a smaller adenoma diameter (p = 0.001). Hypointense female prolactinomas were related to younger age at diagnosis, higher baseline PRL levels and dopamine agonist (DA) resistance (p = 0.009, p = 0.022, p < 0.001, respectively). Hyperintense corticotroph adenomas were related to larger adenoma size and sparsely granulated pattern (p = 0.04, p = 0.017, respectively). There was no significant difference in the recurrence with T2WSI in CD.

Conclusion

Baseline hypointense somatotroph adenomas show a better response to SSA, whereas hypointensity was related to DA resistance in female prolactinomas.
Literatur
1.
Zurück zum Zitat Bonneville JF, Bonneville F, Cattin F (2005) Magnetic resonance imaging of pituitary adenomas. Eur Radiol 15(3):543–548CrossRefPubMed Bonneville JF, Bonneville F, Cattin F (2005) Magnetic resonance imaging of pituitary adenomas. Eur Radiol 15(3):543–548CrossRefPubMed
2.
Zurück zum Zitat Bonneville JF (2016) Magnetic resonance imaging of pituitary tumors. Front Horm Res 45:97–120CrossRefPubMed Bonneville JF (2016) Magnetic resonance imaging of pituitary tumors. Front Horm Res 45:97–120CrossRefPubMed
3.
Zurück zum Zitat Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2):533–538CrossRefPubMed Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2):533–538CrossRefPubMed
4.
Zurück zum Zitat Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Martí C, Halperin I, Webb SM (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973–4978CrossRefPubMed Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Martí C, Halperin I, Webb SM (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973–4978CrossRefPubMed
5.
Zurück zum Zitat Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol 77:72–78CrossRef Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol 77:72–78CrossRef
6.
Zurück zum Zitat Potorac I, Petrossians P, Daly AF, Schillo F, Slama CB, Nagi S, Sahnoun M, Brue T, Girard N, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Cotton F, Delemer B, Higel B, Boulin A, Gaillard S, Luca F, Goichot B, Dietemann JL, Beckers A, Bonneville JF (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22(2):169–177CrossRefPubMed Potorac I, Petrossians P, Daly AF, Schillo F, Slama CB, Nagi S, Sahnoun M, Brue T, Girard N, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Cotton F, Delemer B, Higel B, Boulin A, Gaillard S, Luca F, Goichot B, Dietemann JL, Beckers A, Bonneville JF (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22(2):169–177CrossRefPubMed
7.
Zurück zum Zitat Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Centeno RG, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJ, Delemer B, Petit JM, Schöfl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871–881CrossRefPubMed Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Centeno RG, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJ, Delemer B, Petit JM, Schöfl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871–881CrossRefPubMed
8.
Zurück zum Zitat Shen M, Zhang Q, Liu W, Wang M, Zhu J, Ma Z, He W, Li S, Shou X, Li Y, Zhang Z, Ye H, He M, Lu B, Yao Z, Lu Y, Qiao N, Ye Z, Zhang Y, Yang Y, Zhao Y, Wang Y (2016) Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 58(11):1057–1065CrossRefPubMed Shen M, Zhang Q, Liu W, Wang M, Zhu J, Ma Z, He W, Li S, Shou X, Li Y, Zhang Z, Ye H, He M, Lu B, Yao Z, Lu Y, Qiao N, Ye Z, Zhang Y, Yang Y, Zhao Y, Wang Y (2016) Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 58(11):1057–1065CrossRefPubMed
9.
Zurück zum Zitat Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333–343CrossRefPubMed Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333–343CrossRefPubMed
10.
Zurück zum Zitat Heck A, Emblem KE, Casar-Borota O, Ringstad G, Bollerslev J (2016) MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 53(1):327–330CrossRefPubMed Heck A, Emblem KE, Casar-Borota O, Ringstad G, Bollerslev J (2016) MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 53(1):327–330CrossRefPubMed
11.
Zurück zum Zitat Bakhtiar Y, Hanaya R, Tokimura H, Hirano H, Oyoshi T, Fujio S, Bohara M, Arita K (2014) Geometric survey on magnetic resonance imaging of growth hormone producing pituitary adenoma. Pituitary 17(2):142–149CrossRefPubMed Bakhtiar Y, Hanaya R, Tokimura H, Hirano H, Oyoshi T, Fujio S, Bohara M, Arita K (2014) Geometric survey on magnetic resonance imaging of growth hormone producing pituitary adenoma. Pituitary 17(2):142–149CrossRefPubMed
12.
Zurück zum Zitat Kreutz J, Vroonen L, Cattin F, Petrossians P, Thiry A, Rostomyan L, Tshibanda L, Beckers A, Bonneville JF (2015) Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57(7):679–684CrossRefPubMed Kreutz J, Vroonen L, Cattin F, Petrossians P, Thiry A, Rostomyan L, Tshibanda L, Beckers A, Bonneville JF (2015) Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57(7):679–684CrossRefPubMed
13.
Zurück zum Zitat Kurosaki M, Kambe A, Watanabe T, Fujii S, Ogawa T (2015) Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas. Neurol Res 37(4):341–346CrossRefPubMed Kurosaki M, Kambe A, Watanabe T, Fujii S, Ogawa T (2015) Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas. Neurol Res 37(4):341–346CrossRefPubMed
14.
Zurück zum Zitat Lundin P, Bergstro¨m K, Nyman R, Lundberg PO, Muhr C (1992) Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy. Am J Neuroradiol 13:1279–1291PubMed Lundin P, Bergstro¨m K, Nyman R, Lundberg PO, Muhr C (1992) Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy. Am J Neuroradiol 13:1279–1291PubMed
15.
Zurück zum Zitat Levine SN, Ishaq S, Nanda A, Wilson JD, Gonzalez-Toledo E (2013) Occurence of extensive amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation. Ann Diagn Pathol 7:361–366CrossRef Levine SN, Ishaq S, Nanda A, Wilson JD, Gonzalez-Toledo E (2013) Occurence of extensive amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation. Ann Diagn Pathol 7:361–366CrossRef
16.
Zurück zum Zitat Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C (1992) MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiology 34(1):43–51CrossRefPubMed Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C (1992) MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiology 34(1):43–51CrossRefPubMed
17.
Zurück zum Zitat Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(5):1526–1540CrossRefPubMedPubMedCentral Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(5):1526–1540CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMed Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMed
19.
Zurück zum Zitat Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed
20.
Zurück zum Zitat Asa SL (2011) Tumors of the pituitary gland. Armed Forces Institute of Pathology, Washington, DC Asa SL (2011) Tumors of the pituitary gland. Armed Forces Institute of Pathology, Washington, DC
21.
Zurück zum Zitat Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S (2016) Withdrawal of dopamine agonist therapy in prolactinomas: in which patients when? Pituitary 19(3):303–310CrossRefPubMed Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S (2016) Withdrawal of dopamine agonist therapy in prolactinomas: in which patients when? Pituitary 19(3):303–310CrossRefPubMed
22.
Zurück zum Zitat Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society (2015) Treatment of Cushing’s syndrome: an endcorine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831CrossRefPubMedPubMedCentral Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society (2015) Treatment of Cushing’s syndrome: an endcorine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK (2011) The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing’s disease after transsphenoidal surgery. J Clin Endocrinol Metab 96(7):2057–2064CrossRefPubMedPubMedCentral Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK (2011) The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing’s disease after transsphenoidal surgery. J Clin Endocrinol Metab 96(7):2057–2064CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Boulby P (2004) T2: the transverse relaxation time. In: Tofts P (ed) Quantitative MRI of the brain-measuring changes caused by disease, vol 1. Wiley, Chichester, pp 143–201 Boulby P (2004) T2: the transverse relaxation time. In: Tofts P (ed) Quantitative MRI of the brain-measuring changes caused by disease, vol 1. Wiley, Chichester, pp 143–201
25.
Zurück zum Zitat Kamman RL, Go KG, Brouwer W, Berendsen HJC (1988) Nuclear magnetic resonance relaxation in experimental brain edema: effects of water concentration, protein concentration, and temperature. Magn Reson Med 6:265–274CrossRefPubMed Kamman RL, Go KG, Brouwer W, Berendsen HJC (1988) Nuclear magnetic resonance relaxation in experimental brain edema: effects of water concentration, protein concentration, and temperature. Magn Reson Med 6:265–274CrossRefPubMed
26.
Zurück zum Zitat Potorac I, Petrossians P, Schillo F, Ben slama C, Nagi S, Sahnoun M, Brue T, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Coton F, Delemer B, Higel B, Boulin A, Gaillard S, Goichot B, Dietemann JL, Kreutz J, Tshibanda L, Beckers A, Bonneville JF (2013) Correlations significatives de l’aspect en IRM haute resolution des adénomes hypophysaires à GH avant traitement. Ann Endocrinol 74:259–260CrossRef Potorac I, Petrossians P, Schillo F, Ben slama C, Nagi S, Sahnoun M, Brue T, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Coton F, Delemer B, Higel B, Boulin A, Gaillard S, Goichot B, Dietemann JL, Kreutz J, Tshibanda L, Beckers A, Bonneville JF (2013) Correlations significatives de l’aspect en IRM haute resolution des adénomes hypophysaires à GH avant traitement. Ann Endocrinol 74:259–260CrossRef
27.
Zurück zum Zitat Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102CrossRef Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102CrossRef
28.
Zurück zum Zitat Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325–331CrossRefPubMed Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325–331CrossRefPubMed
29.
Zurück zum Zitat Fideleff HL, Boquete HR, Suárez MG, Azaretzky M (2009) Prolactinoma in children and adolescents. Horm Res 72(4):197–205CrossRefPubMed Fideleff HL, Boquete HR, Suárez MG, Azaretzky M (2009) Prolactinoma in children and adolescents. Horm Res 72(4):197–205CrossRefPubMed
30.
Zurück zum Zitat Nishioka H, Haraoka J, Akada K (2003) Growth potential of prolactinomas in men: is it really different from women? Surg Neurol 59:386–390CrossRefPubMed Nishioka H, Haraoka J, Akada K (2003) Growth potential of prolactinomas in men: is it really different from women? Surg Neurol 59:386–390CrossRefPubMed
31.
Zurück zum Zitat Kitamura K, Nakayama T, Ohata K, Wakasa K, Miki Y (2011) Computed tomography and magnetic resonance imaging appearance of prolactinoma with spheroid-type amyloid deposition. J Comput Assist Tomogr 35(2):313–315CrossRefPubMed Kitamura K, Nakayama T, Ohata K, Wakasa K, Miki Y (2011) Computed tomography and magnetic resonance imaging appearance of prolactinoma with spheroid-type amyloid deposition. J Comput Assist Tomogr 35(2):313–315CrossRefPubMed
32.
33.
Zurück zum Zitat Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schöfl C, Petersenn S, Buslei R (2016) Clinical Impact of the current WHO classification of pituitary adenomas. Endocr Pathol 27(2):104–114CrossRefPubMed Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schöfl C, Petersenn S, Buslei R (2016) Clinical Impact of the current WHO classification of pituitary adenomas. Endocr Pathol 27(2):104–114CrossRefPubMed
34.
Zurück zum Zitat Cazabat L, Dupuy M, Boulin A, Bernier M, Baussart B, Foubert L, Raffin-Sanson ML, Caron P, Bertherat J, Gaillard S (2014) Silent, but not unseen: multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas. Clin Endocrinol 81(4):566–572CrossRef Cazabat L, Dupuy M, Boulin A, Bernier M, Baussart B, Foubert L, Raffin-Sanson ML, Caron P, Bertherat J, Gaillard S (2014) Silent, but not unseen: multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas. Clin Endocrinol 81(4):566–572CrossRef
35.
Zurück zum Zitat Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) World Health Organization classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) World Health Organization classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon
36.
Zurück zum Zitat Syro LV, Rotondo F, Cusimano MD, Di Ieva A, Horvath E, Restrepo LM, Wong M, Killinger DW, Smyth H, Kovacs K (2015) Current status on histological classification in Cushing’s disease. Pituitary 18(2):217–224CrossRefPubMed Syro LV, Rotondo F, Cusimano MD, Di Ieva A, Horvath E, Restrepo LM, Wong M, Killinger DW, Smyth H, Kovacs K (2015) Current status on histological classification in Cushing’s disease. Pituitary 18(2):217–224CrossRefPubMed
37.
Zurück zum Zitat Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol 22(4):443–453CrossRefPubMed Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol 22(4):443–453CrossRefPubMed
38.
Zurück zum Zitat Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s disease survey group. J Clin Endocrinol Metab 80:3114–3120PubMed Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s disease survey group. J Clin Endocrinol Metab 80:3114–3120PubMed
Metadaten
Titel
Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas
verfasst von
Sema Ciftci Dogansen
Gulsah Yenidunya Yalin
Seher Tanrikulu
Sakin Tekin
Nihan Nizam
Bilge Bilgic
Serra Sencer
Sema Yarman
Publikationsdatum
19.02.2018
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 4/2018
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-018-0877-3

Weitere Artikel der Ausgabe 4/2018

Pituitary 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.